Author | Matthew J. Maurer, MS


DLBCL Trials May Exclude Patients Who Need Novel Therapies Most

December 11, 2017

ByMatthew J. Maurer, MS

In this interview we discuss how a short diagnosis-to-treatment interval in newly diagnosed diffuse large B-cell lymphoma is associated with worse outcomes and how this could lead to trials favoring patients with a longer diagnosis-to-treatment interval and better expected outcomes.